​​​​​Clinical Efficacy

Cefoperazone/Sulbactam is recommended as an effective and a safe antibiotic for treating IAIs: Meta-analysis outcomes²

​​​​​​​Overall, the clinical efficacy rates of cefoperazone/sulbactam and comparators were 87.7% and 81.7%, respectively, and cefoperazone/sulbactam was associated with a higher clinical efficacy rate than its comparator (OR, 1.98; 95% CI, 1.31-3.00; I² = 36%; P = 0.10).² ​​​​​​​

Adapted from Lan SH, et al. 2021.

Study Design: In this systematic review and meta-analysis, 12 studies involving 1674 patients were included. The PubMed, Cochrane, Web of Science, Ovid MEDLINE and CNKI databases were searched for relevant articles up to 25 November 2020. The primary outcome was clinical efficacy rate and the secondary outcomes were microbiologic eradication rate, mortality rate and AE risk.²  

Cefoperazone/Sulbactam was associated with a higher microbiologic eradication rate than its comparator in patients with IAI: Meta-analysis outcomes²

Cefoperazone/Sulbactam was associated with a higher microbiologic eradication rate than its comparator (OR, 2.54; 95% CI, 1.72-3.76; I² = 0).² 

Adapted from Lan SH, et al. 2021.

Higher clinical efficacy and lower clinical failure rates in IAIs as compared to the comparators²

Adapted from Lan SH, et al. 2021.

*Comparators included ceftizoxime, clindamycin + gentamicin, ceftriaxone, ciprofloxacin, ceftazidime/amikacin, metronidazole, ceftazidime, cefotaxime, moxifloxacin, Ievofloxacin-cefotaxime-ceftriaxone and tinidazole.
​​​​​​​
​​​​​​​AE, adverse event; CI, confidence interval; CNKI, China National Knowledge Infrastructure; df, degrees of freedom; IAI, intra-abdominal infection; OR, odds ratio.

References :